ArriVent BioPharma (AVBP) Competitors $20.90 -0.18 (-0.86%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. XENE, MLTX, ALVO, IMVT, HCM, ACAD, APLS, AMRX, RXRX, and IBRXShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Immunovant (IMVT), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Xenon Pharmaceuticals MoonLake Immunotherapeutics Alvotech Immunovant HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Recursion Pharmaceuticals ImmunityBio ArriVent BioPharma (NASDAQ:AVBP) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment. Does the media favor AVBP or XENE? In the previous week, Xenon Pharmaceuticals had 12 more articles in the media than ArriVent BioPharma. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 1 mentions for ArriVent BioPharma. Xenon Pharmaceuticals' average media sentiment score of 0.96 beat ArriVent BioPharma's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in AVBP or XENE? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is AVBP or XENE more profitable? Xenon Pharmaceuticals' return on equity of -24.69% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% Xenon Pharmaceuticals N/A -24.69%-23.68% Which has more volatility & risk, AVBP or XENE? ArriVent BioPharma has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Which has better earnings and valuation, AVBP or XENE? ArriVent BioPharma has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-8.20Xenon Pharmaceuticals$9.43M305.12-$182.39M-$3.02-12.45 Does the MarketBeat Community prefer AVBP or XENE? Xenon Pharmaceuticals received 403 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 69.74% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesXenon PharmaceuticalsOutperform Votes42469.74% Underperform Votes18430.26% Do analysts prefer AVBP or XENE? ArriVent BioPharma currently has a consensus target price of $39.00, indicating a potential upside of 85.01%. Xenon Pharmaceuticals has a consensus target price of $56.78, indicating a potential upside of 51.04%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryXenon Pharmaceuticals beats ArriVent BioPharma on 9 of the 17 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$717.06M$6.51B$5.35B$7.51BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-8.207.0021.9518.05Price / SalesN/A260.09396.32104.31Price / CashN/A65.6738.2034.62Price / Book-4.406.346.744.14Net Income-$69.33M$142.49M$3.21B$247.59M7 Day Performance16.21%6.44%3.96%3.51%1 Month Performance4.30%-9.07%-7.03%-5.80%1 Year Performance37.78%-2.74%15.58%2.83% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma0.6837 of 5 stars$20.90-0.9%$39.00+86.6%+33.7%$710.90MN/A-8.1340Gap UpXENEXenon Pharmaceuticals2.7198 of 5 stars$34.70-1.2%$56.78+63.6%-8.5%$2.66B$9.43M-12.30210Analyst UpgradeMLTXMoonLake Immunotherapeutics2.1723 of 5 stars$40.00+4.4%$80.50+101.3%-8.6%$2.56BN/A-31.012News CoverageALVOAlvotech1.695 of 5 stars$8.33+0.5%$18.00+116.1%-37.6%$2.51B$489.68M-4.504IMVTImmunovant1.9272 of 5 stars$14.46-4.6%$41.00+183.5%-49.5%$2.46BN/A-5.52120Analyst ForecastNews CoverageGap UpHigh Trading VolumeHCMHUTCHMED2.0836 of 5 stars$13.89+0.9%$19.00+36.8%-16.7%$2.42B$630.20M0.001,760Gap UpACADACADIA Pharmaceuticals4.1208 of 5 stars$14.38-2.4%$23.93+66.4%-12.5%$2.40B$957.80M18.44510Positive NewsAPLSApellis Pharmaceuticals4.0764 of 5 stars$18.03-0.9%$45.35+151.5%-64.1%$2.26B$781.37M-8.88770Analyst ForecastAMRXAmneal Pharmaceuticals3.0418 of 5 stars$7.13-3.1%$10.80+51.5%+35.3%$2.21B$2.79B-10.497,600Positive NewsGap UpRXRXRecursion Pharmaceuticals2.3613 of 5 stars$5.41-1.6%$8.20+51.6%-27.5%$2.17B$58.49M-3.54400Gap UpIBRXImmunityBio1.8896 of 5 stars$2.51+1.6%$12.19+385.6%-51.0%$2.14B$14.75M-2.73590Analyst Forecast Related Companies and Tools Related Companies Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Alvotech Competitors Immunovant Competitors HUTCHMED Competitors ACADIA Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors ImmunityBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVBP Stock Free AVBP Stock Alerts